CL2013002467A1 - Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. - Google Patents
Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.Info
- Publication number
- CL2013002467A1 CL2013002467A1 CL2013002467A CL2013002467A CL2013002467A1 CL 2013002467 A1 CL2013002467 A1 CL 2013002467A1 CL 2013002467 A CL2013002467 A CL 2013002467A CL 2013002467 A CL2013002467 A CL 2013002467A CL 2013002467 A1 CL2013002467 A1 CL 2013002467A1
- Authority
- CL
- Chile
- Prior art keywords
- cyclodextrin
- hydroxyalkyl
- ophthalmic composition
- droplet
- polyvinylpyrrolidone
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title 2
- 206010010741 Conjunctivitis Diseases 0.000 title 1
- 239000001116 FEMA 4028 Substances 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 229960000686 benzalkonium chloride Drugs 0.000 title 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 title 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 title 1
- 229960004853 betadex Drugs 0.000 title 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 title 1
- -1 hydroxyalkyl β-cyclodextrin Chemical compound 0.000 title 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 title 1
- 229960004114 olopatadine Drugs 0.000 title 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 title 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 title 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487789P | 2011-05-19 | 2011-05-19 | |
| US201161548957P | 2011-10-19 | 2011-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002467A1 true CL2013002467A1 (es) | 2014-05-16 |
Family
ID=46208803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002467A CL2013002467A1 (es) | 2011-05-19 | 2013-08-27 | Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8791154B2 (es) |
| EP (2) | EP3045172A1 (es) |
| JP (1) | JP5940146B2 (es) |
| KR (4) | KR20200053635A (es) |
| CN (1) | CN105534970B (es) |
| AR (1) | AR086490A1 (es) |
| AU (1) | AU2012255046B2 (es) |
| BR (1) | BR112013022057B1 (es) |
| CA (1) | CA2826725C (es) |
| CL (1) | CL2013002467A1 (es) |
| CO (1) | CO6801738A2 (es) |
| ES (1) | ES2587869T3 (es) |
| MX (1) | MX340957B (es) |
| PH (1) | PH12013501808B1 (es) |
| RU (1) | RU2613715C2 (es) |
| TW (1) | TWI544922B (es) |
| UA (1) | UA114597C2 (es) |
| UY (1) | UY34074A (es) |
| WO (1) | WO2012159064A1 (es) |
| ZA (1) | ZA201305870B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610308A8 (pt) | 2005-05-26 | 2017-04-25 | Neuron Systems Inc | Composições e métodos para o tratamento de doença retinal |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| TWI544922B (zh) * | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
| TW201336527A (zh) * | 2012-02-10 | 2013-09-16 | Alcon Res Ltd | 具增強的穩定性之水性藥學組成物 |
| CN105120866B (zh) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| CA2951912A1 (en) * | 2014-06-12 | 2015-12-17 | University Of Notre Dame Du Lac | Composition and method for the treatment of neurological diseases and cerebral injury |
| CA2957548A1 (en) * | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| EP3037094A1 (en) * | 2014-12-23 | 2016-06-29 | Poifa Warszawa SA | Ophthalmic pharmaceutical composition |
| US9707174B2 (en) * | 2015-05-20 | 2017-07-18 | Somerset Therapeutics Llc | Aqueous ophthalmic solution of olopatadine |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CN109069530A (zh) * | 2016-02-28 | 2018-12-21 | 奥尔德拉医疗公司 | 用环糊精治疗过敏性眼部病状 |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CN110431130A (zh) | 2017-03-16 | 2019-11-08 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| DK3740191T3 (da) | 2018-01-18 | 2021-06-07 | Faes Farma Sa | Oftalmiske sammensætninger omfattende bilastin, et beta-cyclodextrin og mindst et geleringsmiddel |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US11197821B2 (en) | 2018-09-25 | 2021-12-14 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
| JP7706758B2 (ja) | 2019-03-26 | 2025-07-14 | アルデイラ セラピューティクス, インコーポレイテッド | 眼科用製剤およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN112263545B (zh) * | 2020-09-16 | 2022-08-23 | 湖北远大天天明制药有限公司 | 一种眼用组合物及其制备方法与应用 |
| WO2025137749A1 (pt) * | 2023-12-27 | 2025-07-03 | Eurofarma Laboratórios S.A. | Processo de solubilização de olopatadina e seu uso |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947573A (en) | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
| US3856919A (en) | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3767788A (en) | 1970-06-08 | 1973-10-23 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3843782A (en) | 1971-07-26 | 1974-10-22 | Flow Pharma Inc | Eye solution and method of using same |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4120949A (en) | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4283393A (en) | 1979-03-13 | 1981-08-11 | Merck & Co., Inc. | Topical application of interferon inducers |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4470965A (en) | 1982-10-27 | 1984-09-11 | Usv Pharmaceutical Corporation | Celiprolol for the treatment of glaucoma |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| GB2169508B (en) | 1985-01-11 | 1989-02-01 | Smith & Nephew Ass | Ophthalmic compositions and use |
| US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| GB8520662D0 (en) | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
| JPS6310784A (ja) | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| CA1317226C (en) | 1987-05-04 | 1993-05-04 | Phillip E. Pennell | Viscoelastic fluid for ophthalmic surgery and method of using same |
| US5068225A (en) | 1987-05-04 | 1991-11-26 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
| US4983585A (en) | 1987-05-04 | 1991-01-08 | Mdr Group, Inc. | Viscoelastic fluid for use in surgery and other therapies and method of using same |
| US4923693A (en) | 1988-01-21 | 1990-05-08 | Sundrops Enterprises, Inc. | Ultraviolet radiation screening method for eyes |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| NZ241310A (en) | 1991-01-17 | 1995-03-28 | Gen Hospital Corp | Trans-splicing ribozymes |
| US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
| DE69333850T3 (de) | 1992-05-06 | 2011-03-17 | Alcon Laboratories, Inc., Fort Worth | Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| CA2153234C (en) | 1993-04-16 | 1999-02-16 | Masanobu Takeuchi | Aqueous drug composition having property of reversible thermosetting gelation |
| CA2125060C (en) | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
| TW274516B (es) | 1993-11-12 | 1996-04-21 | Ciba Geigy Ag | |
| US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US5641805A (en) * | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
| TW434023B (en) | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
| JP4167728B2 (ja) | 1996-02-07 | 2008-10-22 | ロート製薬株式会社 | 粘度を調節した眼科用組成物 |
| US6280745B1 (en) | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| WO1998006381A1 (en) | 1996-08-09 | 1998-02-19 | Alcon Laboratories, Inc. | Preservative systems for pharmaceutical compositions containing cyclodextrins |
| US5888493A (en) | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| US5874418A (en) * | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| EP1004309A4 (en) | 1997-05-27 | 2001-01-17 | Senju Pharma Co | ISRAPAFANT-CONTAINING AQUEOUS COMPOSITIONS |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ATE323110T1 (de) | 1997-07-01 | 2006-04-15 | Pfizer Prod Inc | Verfahren zur herstellung von einem cyclodextrin |
| IT1295423B1 (it) | 1997-10-10 | 1999-05-12 | Medivis S R L | Uso della flunarizina nella terapia topica del glaucoma |
| DE60008730T2 (de) | 1999-06-18 | 2004-08-05 | Alcon Manufacturing Ltd., Fort Worth | Methode zur konzentrationsbestimmung einer amphipathischen antihistaminischen verbindung durch bestimmung ihrer oberflächen aktivitäts einstufung |
| DE19954516A1 (de) | 1999-11-12 | 2001-05-17 | Boehringer Ingelheim Int | Epinastin-haltige Lösungen |
| JP2001158750A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及び抗アレルギー薬の持続性向上方法 |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| KR20020069224A (ko) | 1999-12-27 | 2002-08-29 | 산텐 세이야꾸 가부시키가이샤 | 누액층의 안정화 시스템 |
| PT1250133E (pt) * | 2000-01-25 | 2005-05-31 | Alcon Inc | Composicoes antialergicas oftalmicas adequadas a utilizacao com lentes de contacto |
| AU2001291159A1 (en) | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| WO2002044276A2 (en) | 2000-11-28 | 2002-06-06 | Focal, Inc. | Polyalkylene glycol viscosity-enhancing polymeric formulations |
| WO2003000226A2 (en) | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
| US7977376B2 (en) | 2001-06-27 | 2011-07-12 | Novartis Ag | Olopatadine formulations for topical nasal administration |
| WO2003013481A1 (en) | 2001-08-03 | 2003-02-20 | Bakulesh Mafatlal Khamar | The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients |
| US6828356B2 (en) | 2002-07-29 | 2004-12-07 | Ast Products, Inc. | Preparation of ophthalmic compositions |
| WO2004024126A1 (en) | 2002-09-13 | 2004-03-25 | Cydex, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
| WO2004069157A2 (en) * | 2003-01-17 | 2004-08-19 | Ophthalmic Research Associates, Inc. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US20050250737A1 (en) | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050191270A1 (en) | 2004-02-27 | 2005-09-01 | Hydromer, Inc. | Anti-infectious hydrogel compositions |
| US20050239745A1 (en) | 2004-03-03 | 2005-10-27 | Ophthalmic Research Associates, Inc. | Novel topical ophthalmic formulations |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| WO2006011044A1 (en) | 2004-07-22 | 2006-02-02 | Pfizer Products Inc. | Amorphous cyclodextrin compositions |
| US20080132444A1 (en) | 2004-10-09 | 2008-06-05 | Xiaoling Li | Ocular Agent Delivery Systems |
| PL2486942T3 (pl) * | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| CN101252936A (zh) | 2005-03-02 | 2008-08-27 | 奈森特医药公司 | 眼用组合物的药学可接受的载体 |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| BRPI0708448A2 (pt) | 2006-03-02 | 2011-06-07 | Meiji Seika Kaisha | composição farmacêutica, método para a profilaxia ou tratamento de doenças oftálmicas alérgicas ou doenças nasais alérgicas, e, uso de um composto |
| US7687646B2 (en) | 2006-03-28 | 2010-03-30 | Azad Pharmaceutical Ingredients, Ag | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof |
| US20090136598A1 (en) | 2006-04-26 | 2009-05-28 | Aciex, Inc. | Compositions for the Treatment and Prevention of Eyelid Swelling |
| WO2008015695A2 (en) * | 2006-05-15 | 2008-02-07 | Sun Pharmaceutical Industries Limited | Inclusion complex of olopatadine and cyclodextrin |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| CN101795565A (zh) * | 2007-06-28 | 2010-08-04 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| WO2009041549A1 (ja) | 2007-09-28 | 2009-04-02 | Rohto Pharmaceutical Co., Ltd. | 眼科用組成物 |
| KR20100072333A (ko) | 2007-11-01 | 2010-06-30 | 보오슈 앤드 롬 인코포레이팃드 | 약물 전달을 위한 비히클로서의 비-수성 수혼화성 물질 |
| PL2254549T5 (pl) | 2008-03-17 | 2019-12-31 | Alcon Research, Ltd. | Wodne kompozycje farmaceutyczne zawierające kompleksy boran-poliole |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| US20100010082A1 (en) | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
| EP3943069B1 (en) | 2009-03-17 | 2024-11-27 | Nicox Ophthalmics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
| CN102548536A (zh) * | 2009-10-01 | 2012-07-04 | 爱尔康研究有限公司 | 奥洛他定组合物及其用途 |
| MX2012012941A (es) | 2010-05-07 | 2013-07-29 | Sun Pharma Advanced Res Co Ltd | Nuevas composiciones oftalmicas. |
| TW201206936A (en) * | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
-
2012
- 2012-05-10 TW TW101116676A patent/TWI544922B/zh active
- 2012-05-16 UY UY0001034074A patent/UY34074A/es not_active Application Discontinuation
- 2012-05-18 EP EP16158101.2A patent/EP3045172A1/en not_active Withdrawn
- 2012-05-18 KR KR1020207013081A patent/KR20200053635A/ko not_active Ceased
- 2012-05-18 PH PH1/2013/501808A patent/PH12013501808B1/en unknown
- 2012-05-18 JP JP2014511593A patent/JP5940146B2/ja active Active
- 2012-05-18 KR KR1020167033794A patent/KR101821518B1/ko not_active Ceased
- 2012-05-18 CA CA2826725A patent/CA2826725C/en active Active
- 2012-05-18 AU AU2012255046A patent/AU2012255046B2/en active Active
- 2012-05-18 MX MX2013010039A patent/MX340957B/es active IP Right Grant
- 2012-05-18 KR KR1020187000689A patent/KR20180008868A/ko not_active Ceased
- 2012-05-18 ES ES12725950.5T patent/ES2587869T3/es active Active
- 2012-05-18 UA UAA201309654A patent/UA114597C2/uk unknown
- 2012-05-18 AR ARP120101775A patent/AR086490A1/es not_active Application Discontinuation
- 2012-05-18 CN CN201510933675.6A patent/CN105534970B/zh active Active
- 2012-05-18 US US13/475,607 patent/US8791154B2/en active Active
- 2012-05-18 WO PCT/US2012/038663 patent/WO2012159064A1/en not_active Ceased
- 2012-05-18 RU RU2013140423A patent/RU2613715C2/ru active
- 2012-05-18 EP EP12725950.5A patent/EP2709610B1/en active Active
- 2012-05-18 KR KR1020137023041A patent/KR101689924B1/ko not_active Ceased
- 2012-05-18 BR BR112013022057-0A patent/BR112013022057B1/pt active IP Right Grant
-
2013
- 2013-08-05 ZA ZA2013/05870A patent/ZA201305870B/en unknown
- 2013-08-27 CL CL2013002467A patent/CL2013002467A1/es unknown
- 2013-09-18 CO CO13221623A patent/CO6801738A2/es not_active Application Discontinuation
-
2014
- 2014-06-13 US US14/304,124 patent/US9533053B2/en active Active
-
2016
- 2016-11-22 US US15/358,367 patent/US20170071895A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002467A1 (es) | Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular. | |
| CR20150199A (es) | Análogos de 2´-cloro nucleósido para infección por vhc | |
| CO6741214A2 (es) | Composiciones pesticidas y procesos relacionados | |
| ECSP099319A (es) | Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus | |
| CL2007002207A1 (es) | Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma. | |
| DOP2016000298A (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR064420A1 (es) | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). | |
| GT201300208A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2009000573A1 (es) | Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. | |
| CL2013002125A1 (es) | Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia. | |
| BR112014004550A2 (pt) | sistema de lentes intraoculares controlado por processador | |
| NI200800176A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión | |
| CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
| IT1395519B1 (it) | Pezzo composito, nonche' impiego del pezzo composito | |
| CL2014002048A1 (es) | Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras. | |
| GT201400050A (es) | Derivados de anilina, su preparación y su aplicación terapéutica | |
| UY33509A (es) | Metodos y composiciones para el tratamiento de la alergia | |
| CL2014002918A1 (es) | Derivados de espiro[2.4]heptano puenteados fluorados; composicion farmaceutica y uso como agonistas del receptor de alx en el tratamiento de enfermedades inflamatorias, alergicas. cardiovasculares, entre otras. | |
| CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| ECSP11011101A (es) | Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento | |
| UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
| HN2010000330A (es) | DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION | |
| UY33153A (es) | Formulación tópica oftálmica de péptidos |